|
|
 |
Since our founding in 1953 by Dr. Paul Janssen, and the discovery of HALDOL® (haloperidol) in 1958, Janssen has been firmly grounded in science and the search for innovation. That focus and commitment are nurtured by a unique blend of "opposites" - a lean, entrepreneurial size and organization that allow Janssen to be nimble and opportunistic - backed by the significant resources of Johnson & Johnson, our parent company and the world's most comprehensive manufacturer of healthcare products. This combination has led to a rich history of success.
The drug discovery organization of Johnson & Johnson, Johnson & Johnson Pharmaceutical Research & Development, L.L.C., (J&JPRD), combines the former Janssen Research Foundation and R.W. Johnson Pharmaceutical Research Institute (PRI). Together they are credited with synthesizing more than 84,000 new chemical compounds — leading to the introduction of more than 75 medications in 150 countries that treat disabling or life-threatening conditions such as cancer, mental illness and intractable pain. Four of those medications are now included on the World Health Organization's Essential Drug List.
These drugs represented "firsts" in their class at the time they were introduced and have blazed the trail for other products that have followed.
J&JPRD is interested in all areas of mental health, including schizophrenia and other psychotic disorders, bipolar disorders, depressive disorders, anxiety spectrum disorders, substance abuse and addiction, and Attention Deficit Hyperactivity Disorder (ADHD).
Our scientific efforts and ongoing search for innovation have led to many publications in prominent medical journals, to hundreds of scientific presentations at professional medical meetings, as well as to continued product development and subsequent regulatory filings. See News Center for recent announcements regarding these efforts.
|
|
|
|
|
 |
